Biocon Ltd 2020 AR2
The report details Biocon's performance for the fiscal year 2020, highlighting a 15% growth in consolidated revenue to ₹65,286 million. Key achievements include crossing the ₹20,000 million milestone in both the Small Molecules and Research Services segments. The company launched its 'Mission 10 cents' initiative to facilitate universal access to recombinant human insulin in low- and middle-income countries. Additionally, Biocon Biologics received US FDA approval for its biosimilar Insulin Glargine, Semglee, and successfully commercialized biosimilar Trastuzumab, Ogivri, in the United States.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 314
Back to company
Biocon Ltd
Annual Report
The report details Biocon's performance for the fiscal year 2020, highlighting a 15% growth in consolidated revenue to ₹65,286 million. Key achievements include crossing the ₹20,000 million milestone in both the Small Molecules and Research Services segments. The company launched its 'Mission 10 cents' initiative to facilitate universal access to recombinant human insulin in low- and middle-income countries. Additionally, Biocon Biologics received US FDA approval for its biosimilar Insulin Glargine, Semglee, and successfully commercialized biosimilar Trastuzumab, Ogivri, in the United States.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees